<DOC>
	<DOCNO>NCT00523991</DOCNO>
	<brief_summary>A 24 week , randomize , double-blind , placebo-controlled , multicenter study evaluate efficacy safety 18mcg tiotropium inhalation capsule administer Handihaler daily plus Pro Re Nata ( PRN ) albuterol ( salbutamol ) vs. placebo plus PRN albuterol ( salbutamol ) chronic obstructive pulmonary disease subject naive maintenance therapy .</brief_summary>
	<brief_title>Trial Comparing Tiotropium Inhalation Capsules v Placebo Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : All subject must diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) accord Global Initiative Chronic Obstructive Pulmonary Disease ( GOLD ) guideline criterion : postbronchodilator Forced Expiratory Volume one Second/Forced Vital Capacity ( FEV1/FVC ) ratio &lt; 70 % ( visit 1 ) . Subjects must GOLD Stage II postbronchodilator FEV1 &gt; 50 % &lt; 80 % predict normal ( visit 1 ) . Subjects must current exsmokers smoke history &gt; =10 pack year . Subjects must Medical Research Council ( MRC ) dyspnea score &gt; = 2 . Exclusion criterion : Subjects treat maintenance medication chronic respiratory disease within six month prior screen . Subjects significant disease COPD . Subjects chronic systemic corticosteroid . Subjects upper and/or lower respiratory tract infection COPD exacerbation 6 week prior initial visit 1 screening period prior visit 3 Subjects recent ( past 6 month ) myocardial infarction , unstable life threaten cardiac arrhythmia require intervention change drug therapy last year ; hospitalize cardiac failure past year .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>